Evaluation of teniposide (VM-26)-induced toxicity on mouse spermatogenesis by flow cytometry.
Alteration in the testicular weight and various germ cell populations was studied in male mice treated with different doses (0.05, 0.25, 0.5, 1.0 and 2.0 mg/kg b. wt.) of teniposide (VM-26) at various post-treatment time periods. Treatment of mice with different doses of teniposide did not significantly alter the testicular weights, irrespective of the drug dose used. Flow-cytometric analysis of germ cells of the untreated control mice testes revealed four distinct DNA peaks corresponding to elongated spermatids (HC), round spermatids (1C), spermatogonia and non-germ cells (2C) and primary spermatocytes (4C). The region between 2C and 4C peaks represents cells that are actively synthesizing DNA (S-phase cells). Treatment of mice with different doses of teniposide resulted in a significant depletion in the relative percentage of spermatogonia from day 2 to 35 post-treatment depending on the drug dose. DNA-synthesizing, i.e. S-phase, cells declined significantly at day 1 post-treatment and continued to decline up to day 70 post-treatment for all the drug doses studied, except 2 mg/kg drug dose at day 28 post-treatment. A significant decline in the relative percentage of primary spermatocytes (4C) was observed at day 7 that continued up to day 70 post-treatment depending on the drug dose. Round spermatids (1C) declined significantly at day 21 post-treatment after administration of 0.25--2.0 mg/kg VM-26. The relative percentage of elongated spermatids showed a significant decline at day 28 after 1 and 2 mg/kg drug treatment. These alterations in different germ-cell populations are reflected in the various germ-cell ratios. The 4C:2C ratio showed a significant decline at day 7 and 14 post-treatment after 1 and 2 mg/kg VM-26 treatment, while the 1C:2C ratio declined significantly at day 21 post-treatment in the mice treated with 0.5 and 2.0 mg/kg of VM-26. 4C:S-phase and 1C:4C ratios increased significantly from day 1 to 70 post-treatment, depending on the drug dose. Our study demonstrates that the treatment of mice with low doses of VM-26 exerts cytotoxic effects on various germ-cell populations.
Jyothi
P
P
Department of Radiobiology, Kasturba Medical College, Manipal-576 119, India.
Jagetia
G C
GC
Krishnamurthy
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001835:Body Weight; D004171:Diploidy; D004305:Dose-Response Relationship, Drug; D004996:Ethidium; D005434:Flow Cytometry; D005456:Fluorescent Dyes; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D009929:Organ Size; D013076:Sperm Count; D013091:Spermatogenesis / Q000187:drug effects*; D013094:Spermatozoa / Q000145:classification / Q000187:drug effects* / Q000473:pathology; D013713:Teniposide / Q000633:toxicity*; D013737:Testis / Q000187:drug effects / Q000473:pathology; D013997:Time Factors
D000970:Antineoplastic Agents; D005456:Fluorescent Dyes; D013713:Teniposide; D004996:Ethidium